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Background: Coeliac disease is a common enteropathy characterized by an increased mortality mainly due to its
complications. The natural history of complicated coeliac disease is characterised by two different types of course:
patients with a new diagnosis of coeliac disease that do not improve despite a strict gluten-free diet (type A cases)
and previously diagnosed coeliac patients that initially improved on a gluten-free diet but then relapsed despite a
strict diet (type B cases). Our aim was to study the prognosis and survival of A and B cases.
Methods: Clinical and laboratory data from coeliac patients who later developed complications (A and B cases) and
sex- and age-matched coeliac patients who normally responded to a gluten-free diet (controls) were collected
among 11 Italian centres.
Results: 87 cases and 136 controls were enrolled. Complications tended to occur rapidly after the diagnosis of
coeliac disease and cumulative survival dropped in the first months after diagnosis of complicated coeliac disease.
Thirty-seven cases died (30/59 in group A, 7/28 in group B). Type B cases presented an increased survival rate
compared to A cases.
Conclusions: Complicated coeliac disease is an extremely serious condition with a high mortality and a short
survival. Survival depends on the type of natural history.
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Coeliac disease (CD), a chronic gluten-induced enterop-
athy, is common in western populations [1]. Although
its prognosis is excellent in the great majority of cases,
some of these patients may develop serious complications,
such as refractory CD type 1 (RCD1), refractory CD type
2 (RCD2), ulcerative jejuno-ileitis (UJI), enteropathy asso-
ciated T cell lymphoma (EATL), abdominal B cell lymph-
oma (ABL), small bowel carcinoma (SBC) and collagenous
sprue (CS) [2-6]. Since treatment is hardly effective [7],* Correspondence: f.biagi@smatteo.pv.it
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In particular, five-year survival is between 80% and 96% in
patients with RCD1, between 40% and 58% in patients
with RCD2 and drops to less than 20% in patients with
CD complicated by EATL [8-13]. These conditions have
traditionally been considered the major complications of
CD [14]. Moreover, since most of them share a common
pathogenetic link [15], it is certainly possible to consider
them altogether as complicated CD (CCD).
There are various factors correlated with the risk of
developing CD complications. It has been known for
some time that the main risk factor is poor compliance
with a gluten-free diet (GFD) and, in the last few years,
it has emerged that the clinical form of CD at diagnosisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the diagnostic delay of CD, age at diagnosis of CD, and
homozygosity for HLA-DQ2 also correlate with the
risk of developing complications and thus with mortal-
ity [17-23]. Despite this additional knowledge, there
are still many obscure aspects.
The natural history of CCD has not yet been the subject
of specifically focussed studies. According to our experi-
ence, there are two different ways in which CCD can de-
velop clinically [24]. In some patients, the complication of
CD is diagnosed shortly after the diagnosis of CD itself
and the introduction of a strict GFD does not result in a
significant clinical improvement (for the purpose of
this paper we define these patients as “type A cases”).
Conversely, in other patients the diagnosis of CCD is
made after a period of time during which the introduction
of a strict GFD is followed by a remission of the symptoms
that had led to the initial diagnosis of CD. Subsequently,
however, the reappearance of malabsorption, abdominal
pain, fever, or anaemia arouses the suspicion that a compli-
cated form of CD is developing (“type B cases”). The preva-
lence and, above all, the prognosis of these two different
forms of onset of CCD have not yet been ascertained.
The aim of this study was to investigate the natural
history of CCD and to clarify its evolution and prognosis.
Patients and methods
Design of the study
To collect a sufficient number of patients, we organised
a retrospective multicenter case–control study based on
collection of clinical and laboratory data.
Cases and controls
Cases were recruited among adult coeliac patients
(age > 18 years), who, between 1990 and 2010, were
diagnosed with any of the following complications:
RCD1, RCD2, UJI, EATL, ABL, SBC, CS. Diagnoses of
EATL, ABL, SBC, and CS were based on morphological
criteria; diagnosis of RCD2 was based on a flat duodenal
mucosa not responding to 12 months on a GFD and evi-
dence of an aberrant intraepithelial lymphocyte population
and/or gamma-chain T-cell monoclonal rearrangement;
diagnosis of RCD1 was based on a flat duodenal mucosa
not responding to 12 months on a GFD but without the
diagnostic criteria for RCD2; diagnosis of UJI was based
on the demonstration of small bowel ulcers but without
the diagnostic criteria for EATL and RCD2 [3,9-12].
Cases were divided into types A and B according to the
type of natural history (see introduction). Other causes
of villous atrophy or clinically nonresponsive CD were
excluded [25,26].
Controls were recruited among adult patients (age >
18 years) found to be affected by CD on the basis of a
flat duodenal biopsy and positive endomysial/tissuetransglutaminase antibodies while on a gluten-containing
diet. They all clinically responded to a GFD and none of
them developed any of the above mentioned complications.
Two cases, or at least one, were matched to cases by gen-
der, age at diagnosis of CD (±5 years), year of first observa-
tion by the cooperating centre and length of follow-up.
Data collection
Date of birth, gender, date of diagnosis of CD, pattern of clin-
ical presentation of CD (classic, non classic, asymptomatic)
[16], adherence to a GFD evaluated by means of a dietary
interview, clinical response to a GFD, date of diagnosis
of CCD, type of complication, date and cause of death
(if the subject is still alive, date of the last time he/she was
seen in the clinic) are the very simple clinical data we col-
lected for each case and each control. Haemoglobin, RDW,
albumin, Na+, K+, Ca++, total cholesterol, triglycerides, glu-
cose, ESR, and CRP, at the time of diagnosis of CD, are the
laboratory tests we evaluated in cases and controls.
Statistics
The data obtained were analysed by means of descriptive
statistics, Student’s T test, and Mann–Whitney test where
appropriate. To study the survival over time of patients
with CCD we calculated the cumulative probability curve
by means of the Kaplan-Meier method. The complication-
free survival was calculated from the date of diagnosis of
CD to that of diagnosis of complication, whereas the sur-
vival of the CCD patients were calculated from the date
of diagnosis of complication to that of last known vital
status. The logrank analysis, performed according to the
Mantel-Cox method, and evaluated the presence of any
differences between the curves obtained [27,28].
The study protocol conforms to the ethical guidelines
of the 1975 Declaration of Helsinki (6th revision, 2008)
as reflected in a priori approval by the institution's hu-
man research committee (Fondazione IRCCS Policlinico
San Matteo).
Results
Clinical study
Eleven Italian centres, distributed throughout the country,
took part in the study, allowing us to collect the clinical
data of 87 cases (55 females, mean age at diagnosis of CD
51.2 ± 14.3 years, median follow-up from the diagnosis of
CD 6.4 years, range 0.1-30.3) and 136 controls (89 females,
49.2 ± 13.3 years). Twenty of them were affected by RCD1,
3 by RCD2, 17 UJI, 17 EATL, 6 ABL, 16 SBC, and 1 CS. In
seven patients with RCD, the available data did not make it
possible to distinguish between RCD1 and RCD2 (RCDX).
Table 1 shows the main clinical results. As expected,
clinical type of CD, adherence to a GFD and mortality
were significantly different in the two groups. Figure 1
shows the Kaplan Meier curve calculated on the basis
Table 1 Demographic and clinical data in complicated
coeliac disease (cases) and in coeliac patients responding
to a gluten-free diet (controls)
Cases Controls p
Number (Females) 87 (55) 136 (89) NS*
Age at diagnosis of CD
(mean year ± sd)
51 ± 14 49 ± 13 NS**
Age at diagnosis of CCD
(mean year ± sd)
54 ± 13 N.A.
Classic form at diagnosis of CD 86/87 (99%) 85/136 (63%) <0.0001*
Strict adherence to a
gluten-free diet
66/87 (76%) 129/136 (95%) <0.0001*
Years between diagnosis of
CD and diagnosis of CCD:
median (25°, 75° percentile)
1.4 (0.1, 3.8) N.A.
Mortality 37/87 (43%) 0/136 (0%) <0.0001*
Years between diagnosis of
CCD and death: median
(25°, 75° percentile)
1.0 (0.1, 2.9) N.A.
*Chi2 test, **t test, CD = coeliac disease; CCD = complicated coeliac disease;
N.A. = not allowed; NS = not significant.
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veloped the complication soon after the diagnosis of
CD, there is no limit beyond which the complications
of CD no longer develop.
Table 2 show the clinical data of the cases divided ac-
cording to the type of natural history. In 59 cases (68%)
the complication arose without GFD, introduced after
the initial diagnosis of CD based on flat duodenal biopsy,
positive coeliac antibodies and/or coeliac HLA, having led
to a considerable improvement in symptoms (type A cases).
EATL affected 16 patients, UJI 13, SBC 12, RCD1 8, RCD2
1, RCDX 4, and ABL 5. Only 28 of them (47%) were still
alive when these data were collected. Apart from five cases
who died of cardiovascular diseases (3), Paget disease (1),Figure 1 Kaplan Meier curve showing the cumulative
complication-free survival from diagnosis of coeliac disease
until diagnosis of complicated coeliac disease in the 87 cases.and lung cancer (1), the other cases all died because of the
condition complicating CD.
In the last 28 cases (32%), a diagnosis of CCD was
reached after a period of time (median 5.0 years, 25th-75th
percentile 3.3-8.1 years) in which the GFD had led to a re-
mission of the malabsorption symptoms that had triggered
the diagnosis of CD (cases type B). RCD1 was diagnosed
in 12 patients, RCD2 in 2, RCDX in 3, UJI in 4, SBC in 4,
EATL, ABL, and CS in one patient each. Twenty-one out
of 28 (75%) were still alive at the time when these data were
collected; the other cases all died because of the condition
complicating CD.
Table 3 shows the main laboratory test results at the
time of diagnosis of CD in cases and controls. Already at
the time of diagnosis of CD, levels of haemoglobin,
albumin, cholesterol and serum electrolytes were lower
than in controls. Conversely, inflammatory markers
were higher than in controls.
As far as possible differences between type A and
type B cases are concerned, there was no difference
between these two groups in any of the laboratory
tests, apart from triglyceride levels that were higher in
type A cases (133.5 mg/dL ± 74.8) than in type B cases
(87.0 mg/dL ± 31.4).
Survival study
The mortality of this condition is extremely high, since
only 50 out of the 87 cases (58%) were still alive when
these data were collected. Figure 2 shows the cumulative
survival of the 87 cases, starting from the time at which
CCD was diagnosed. It can be observed that survival
was drastically reduced in the first 6 months and contin-
ued to be reduced, albeit more slowly, up to 5 years after
the diagnosis of CCD. Once this limit has been passed,
the survival seems to stabilize.
Figure 3 shows the cumulative survival at 10 years
according to the two different types of natural history.
Type B cases presented an increased survival rate com-
pared to type A cases (logrank, p = 0.0006).
Cumulative 10-year survival according to the histo-
pathological subtype of CCD, analysed by means of
Kaplan Meyer curves and subsequent logrank analysis,
did not show any statistically significant differences
(data not shown). It is, however, likely that this could
be due to the fact that it was necessary to divide the
cases into six subgroups, with an inevitable reduction
of statistical power.
Discussion
This study investigates the natural history of CCD and
provides both new results and confirmation of results
already reported in the literature.
Although the complications of CD tend to develop just
after the diagnosis of CD in most cases, these complications
Table 2 Demographic and clinical data in the two forms
of complicated coeliac disease: type A cases, coeliac
patients who never responded to a gluten-free diet, type
B cases, coeliac patients who initially responded to a
gluten-free diet but then relapsed
Cases
type A
Cases
type B
p
Number (Females) 59 (32) 28 (23) 0.02*
Age at diagnosis of CD
(mean years ± sd)
53 ± 14 47 ± 14 NS**
Age at diagnosis of CCD
(mean year ± sd)
54 ± 13 54 ± 13 NS**
Strict adherence to a
gluten-free diet
45/59 (83%) 21/28 (75%) NS*
Years between diagnosis of CD
and diagnosis of CCD: median
(25th, 75th percentile)
0.3 (0.1, 1.4) 4.9 (3.3, 8.1) <0.0001***
Mortality 30/59 (51%) 7/28 (25%) 0.03*
Years between diagnosis of
CCD and death: median
(25th, 75th percentile)
1.0 (0.1, 2.7) 2.3 (0.3, 4.2) NS***
*Chi2 test, **t test, ***Mann–Whitney test, CD= coeliac disease; CCD= complicated
coeliac disease; NS = not significant.
Biagi et al. BMC Gastroenterology 2014, 14:139 Page 4 of 6
http://www.biomedcentral.com/1471-230X/14/139can also arise even after many years (Figure 1). This con-
firms the well-known importance of maintaining a regular
clinical follow up in all coeliac patients, especially those di-
agnosed in adulthood. Very interestingly, we demonstrated
that on the basis of the initial response to a GFD it is pos-
sible to identify two different clinical forms of CCD and
that these present substantial differences in terms of survival
(Figure 3). In patients who develop a complication after re-
mission of the symptoms that led to the initial diagnosis of
CD (type B cases), the prognosis is better than in patients in
whom the complication of CD developed without the initialTable 3 Mean ± standards deviation of the laboratory
findings in patients with complicated coeliac disease
(cases) and in coeliac patients responding to a gluten-free
diet (controls)
Cases Controls p
Haemoglobin (g/dL) 11.0 ± 2.1 12.0 ± 2.2 0.0038
RDW (%) 13.8 ± 2.0 15.4 ± 6.9 NS
ESR* (mm/h) 20 (9–35) 10 (6.8-15) 0.005
CRP* (mg/dL) 0.9 (0.5-1.9) 0.4 (0.3-0.5) < 0.0001
Albumin (g/dL) 3.2 ± 0.7 4.1 ± 0.6 0.0001
Na+ (mEq/L) 137.9 ± 6.9 141.1 ± 3.5 0.03
K+ (mEq/L) 4.1 ± 0.7 4.3 ± 0.4 0.02
Ca++ (mEq/L) 8.2 ± 1.2 9.2 ± 0.5 < 0.0001
Total cholesterol (mg/dL) 145.9 ± 39.7 183.3 ± 45.7 < 0.0001
Triglycerides (mg/dL) 110.3 ± 61.3 102.5 ± 46.7 NS
Glucose (mg/dL) 90.0 ± 14.8 89.7 ± 18.8 NS
*median and 25th-75th inter-quartile range.symptoms ever going into remission (type A cases). To
explain this finding, we noted that EATL, UJI and SBC
are more frequent among cases type A than cases type
B. On the other hand, RCD1 is more frequent among
cases type B. Thus, we could hypothesise that, in those
coeliac patients who developed complications very rapidly
without GFD being able to induce any remission of the
symptoms, a malignant complication had already been trig-
gered when CD was diagnosed. The course of the disease
was therefore much more aggressive. Finally, since now-
adays there is no efficient treatment for these complications
[7], this finding is unlikely to have an immediate, strong
clinical impact. Nevertheless, it certainly helps in better
understanding the clinical course of these conditions and
in figuring out their prognoses.
As regards the different histopathological subtypes, we
showed that RCD, UJI, and EATL, the complications well-
known to share a common pathogenetic link [15], are defin-
itely the most common complications (64/87, 73.5%), SBC
and ABL occur in 18% and 7% of the cases respectively, and
CS seems to be exceptionally rare. Having found that almost
75% of the cases share a common pathogenetic link and
that the others are affected by abdominal malignancies
certainly supports are choice of considering all the cases as
affected by CCD. According to our data, survival in each of
these subtypes does not appear to be significantly different.
However, since the literature reports very different survival
rates for each of these subtypes of complication [8-12], we
believe that our result is due to the relatively limited size of
our sample rather than to a really similar mortality.
Patients with RCD2 have already been found to be
significantly more anaemic and hypoalbuminemic than
patients with RCD1 [29]. Here we show that, already at
the time of diagnosis of CD, not only haemoglobin and
albumin but also electrolytes and cholesterol are signifi-
cantly reduced in coeliac patients who will later developFigure 2 Kaplan Meier curve showing the cumulative survival
from diagnosis of complicated coeliac disease until time of
death in the 87 cases.
Figure 3 Kaplan Meier curve showing the cumulative survival
from diagnosis of complicated coeliac disease until time of
death in the 87 cases divided according to the type of natural
history of disease. Thin line: type B cases, who initially responded
to a gluten-free diet; thick line: type A cases, who never responded
to a strict gluten-free diet.
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respond to a GFD. The reason why these nutritional
parameters are lower in the first ones is likely to be
linked to the fact that they are almost always affected
by a classic/major form of CD (Table 1). On the other
hand, the increased levels of ESR and CRP we found in
some cases suggest that an increased systemic inflam-
matory response, likely to be linked to the onset of the
complication, was already present at the time of diag-
nosis of CD.
Our study made it possible to confirm a series of results
already present in the literature, and this is an obvious
demonstration of the validity of all our results. In particu-
lar, we confirm that the complications of CD are burdened
by a high rate of mortality and that death occurs soon
after the diagnosis of the complication (Figure 2). We also
confirmed that coeliac patients who do not adhere to a
strict GFD, with symptoms of classic CD at the onset and
with a diagnosis late in life are at greater risk of developing
these complications [18].
This study also presents some problems, linked fun-
damentally to its retrospective and multicentre nature.
The study is based on 87 cases who had been attending
11 different Italian centres over the last 15 years; 37 of
them were already dead when the data were collected.
Moreover, the diagnoses of the CCD subtypes were
those made by the individual centres and it was not
possible to bring them into line. While this is probably
not a problem as regards the diagnosis of lymphoma
and cancer of the small intestine, it is inevitable that it
influenced the differential diagnosis between RCD1
and RCD2, a diagnosis that has only been possible for a
few years and certainly not in all centres. This type ofproblem is, on the other hand, well known and already
reported in the literature [5]. Moreover, in seven of our
cases of RCD the available data did not make it pos-
sible to distinguish between type 1 and 2. Evaluation of
the strictness of a GFD was also necessarily based on
the clinical judgement of each centre, without it being
possible to even out this evaluation. Finally, our me-
dian follow up was rather short (2,9 years). However,
this was due to the rapid onset of most complications
and to their severe prognosis.
These organisational problems could be resolved with
a prospective study. This is, however, very difficult to or-
ganise. Since CCD develops in less than 1% of patients
[4-6,8], then to enrol at least 100 patients with CCD we
would have to diagnose at least 10000 new adult patients
with CD, follow them for several years before identifying
those that will develop a complication and then study
their clinical evolution and survival.
Conclusions
Our study reveals previously unrecognised, interesting
and innovative aspects of CCD. While on one hand we
have in fact confirmed a series of data already present in
the literature, on the other we have identified two clin-
ical subtypes of CCD distinguished on the basis of the
initial clinical response to a GFD and on survival.
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